Cargando…

Temozolomide, Simvastatin and Acetylshikonin Combination Induces Mitochondrial-Dependent Apoptosis in GBM Cells, Which Is Regulated by Autophagy

SIMPLE SUMMARY: Glioblastoma multiforme (GBM) is a deadly brain tumor. The current chemotherapy strategies (including using temozolomide (TMZ)) is not very effective for GBM patients. Therefore, finding a new therapeutic strategy is demanding in the field of GBM. In our current investigations, we us...

Descripción completa

Detalles Bibliográficos
Autores principales: Hajiahmadi, Sima, Lorzadeh, Shahrokh, Iranpour, Rosa, Karima, Saeed, Rajabibazl, Masoumeh, Shahsavari, Zahra, Ghavami, Saeid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953749/
https://www.ncbi.nlm.nih.gov/pubmed/36829578
http://dx.doi.org/10.3390/biology12020302
Descripción
Sumario:SIMPLE SUMMARY: Glioblastoma multiforme (GBM) is a deadly brain tumor. The current chemotherapy strategies (including using temozolomide (TMZ)) is not very effective for GBM patients. Therefore, finding a new therapeutic strategy is demanding in the field of GBM. In our current investigations, we used an innovative combination of TMZ, and an FDA-approved, cholesterol-lowering medication (simvastatin), and a Chinese herbal medicine derivative (acetylshikonin) in GBM cell lines. Our investigation showed that the triple-combination treatment (TMZ/Simva/ASH) induced significantly more cell death via damaging the energy engine of the cells (mitochondria). In addition, inhibition of the cellular self-eating mechanism (autophagy) sensitizes the GBM to triple-combination-induced cell death. Overall, the current research may open new avenues in the treatment of GBM patients in the long term. ABSTRACT: Glioblastoma multiforme (GBM) is one of the deadliest cancers. Temozolomide (TMZ) is the most common chemotherapy used for GBM patients. Recently, combination chemotherapy strategies have had more effective antitumor effects and focus on slowing down the development of chemotherapy resistance. A combination of TMZ and cholesterol-lowering medications (statins) is currently under investigation in in vivo and clinical trials. In our current investigation, we have used a triple-combination therapy of TMZ, Simvastatin (Simva), and acetylshikonin, and investigated its apoptotic mechanism in GBM cell lines (U87 and U251). We used viability, apoptosis, reactive oxygen species, mitochondrial membrane potential (MMP), caspase-3/-7, acridine orange (AO) and immunoblotting autophagy assays. Our results showed that a TMZ/Simva/ASH combination therapy induced significantly more apoptosis compared to TMZ, Simva, ASH, and TMZ/Simva treatments in GBM cells. Apoptosis via TMZ/Simva/ASH treatment induced mitochondrial damage (increase of ROS, decrease of MMP) and caspase-3/7 activation in both GBM cell lines. Compared to all single treatments and the TMZ/Simva treatment, TMZ/Simva/ASH significantly increased positive acidic vacuole organelles. We further confirmed that the increase of AVOs during the TMZ/Simva/ASH treatment was due to the partial inhibition of autophagy flux (accumulation of LC3β-II and a decrease in p62 degradation) in GBM cells. Our investigation also showed that TMZ/Simva/ASH-induced cell death was depended on autophagy flux, as further inhibition of autophagy flux increased TMZ/Simva/ASH-induced cell death in GBM cells. Finally, our results showed that TMZ/Simva/ASH treatment potentially depends on an increase of Bax expression in GBM cells. Our current investigation might open new avenues for a more effective treatment of GBM, but further investigations are required for a better identification of the mechanisms.